Immatics Announces Third Quarter 2026 Financial Results
Immatics N.V. reported its financial results for the third quarter ended September 30, 2026, highlighting an increase in revenue alongside a wider net loss compared to the same period in 2025.
Stocks · News reference
Dr. Ali Mohammed of Immatics Biotechnologies joined other industry experts at the Cellex Symposium 2026 to discuss artificial intelligence in regulated environments and manufacturing quality.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immatics N.V. reported its financial results for the third quarter ended September 30, 2026, highlighting an increase in revenue alongside a wider net loss compared to the same period in 2025.
Immatics reported Q3 2026 financial results with cash position of $536.3 million and announced enrollment progress in the Phase 3 SUPRAME trial for anzu-cel (IMA203) in advanced melanoma, with topline data expected in H1 2027. Updated clinical data presented at ESMO Congress 2026 showed IMA203CD8 achieved 55% cORR in gynecologic cancers and IMA402 bispecific demonstrated 32% cORR in PRAME-high melanoma with 91% 1-year OS rate. The company continues advancing its PRAME-targeted cell therapy and bispecific programs across multiple cancer indications.
Immatics reported positive clinical data for its PRAME-targeting therapies, IMA402 and IMA203CD8, during oral presentations at the 2026 ESMO Annual Meeting.
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
Stifel analyst Laura Prendergast initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target of $15.